168 related articles for article (PubMed ID: 27197155)
1. Oncogenic Mutation of AIMP2/p38 Inhibits Its Tumor-Suppressive Interaction with Smurf2.
Kim DG; Lee JY; Lee JH; Cho HY; Kang BS; Jang SY; Kim MH; Guo M; Han JM; Kim SJ; Kim S
Cancer Res; 2016 Jun; 76(11):3422-36. PubMed ID: 27197155
[TBL] [Abstract][Full Text] [Related]
2. AIMP2 promotes TNFalpha-dependent apoptosis via ubiquitin-mediated degradation of TRAF2.
Choi JW; Kim DG; Park MC; Um JY; Han JM; Park SG; Choi EC; Kim S
J Cell Sci; 2009 Aug; 122(Pt 15):2710-5. PubMed ID: 19584093
[TBL] [Abstract][Full Text] [Related]
3. Akt SUMOylation regulates cell proliferation and tumorigenesis.
Li R; Wei J; Jiang C; Liu D; Deng L; Zhang K; Wang P
Cancer Res; 2013 Sep; 73(18):5742-53. PubMed ID: 23884910
[TBL] [Abstract][Full Text] [Related]
4. p16Ink4a suppression of lung adenocarcinoma by Bmi-1 in the presence of p38 activation.
Lee MO; Lee HJ; Kim MA; Kim EK; Lee JH; Heo JH; Lee SH; Cho SH; Fornace AJ; Jeong HC; Cha HJ
J Thorac Oncol; 2011 Mar; 6(3):423-31. PubMed ID: 21164364
[TBL] [Abstract][Full Text] [Related]
5. Downregulation of FUSE-binding protein and c-myc by tRNA synthetase cofactor p38 is required for lung cell differentiation.
Kim MJ; Park BJ; Kang YS; Kim HJ; Park JH; Kang JW; Lee SW; Han JM; Lee HW; Kim S
Nat Genet; 2003 Jul; 34(3):330-6. PubMed ID: 12819782
[TBL] [Abstract][Full Text] [Related]
6. AIMP2-DX2 provides therapeutic interface to control KRAS-driven tumorigenesis.
Kim DG; Choi Y; Lee Y; Lim S; Kong J; Song J; Roh Y; Harmalkar DS; Lee K; Goo JI; Cho HY; Mushtaq AU; Lee J; Park SH; Kim D; Min BS; Lee KY; Jeon YH; Lee S; Lee K; Kim S
Nat Commun; 2022 May; 13(1):2572. PubMed ID: 35546148
[TBL] [Abstract][Full Text] [Related]
7. TSGΔ154-1054 splice variant increases TSG101 oncogenicity by inhibiting its E3-ligase-mediated proteasomal degradation.
Chua HH; Huang CS; Weng PL; Yeh TH
Oncotarget; 2016 Feb; 7(7):8240-52. PubMed ID: 26811492
[TBL] [Abstract][Full Text] [Related]
8. E3 ubiquitin ligase FBW7α inhibits cholangiocarcinoma cell proliferation by downregulating c-Myc and cyclin E.
Li M; Ouyang L; Zheng Z; Xiang D; Ti A; Li L; Dan Y; Yu C; Li W
Oncol Rep; 2017 Mar; 37(3):1627-1636. PubMed ID: 28184929
[TBL] [Abstract][Full Text] [Related]
9. The C-terminus of Hsp70-interacting protein promotes Met receptor degradation.
Jang KW; Lee JE; Kim SY; Kang MW; Na MH; Lee CS; Song KS; Lim SP
J Thorac Oncol; 2011 Apr; 6(4):679-87. PubMed ID: 21325980
[TBL] [Abstract][Full Text] [Related]
10. JTV1 co-activates FBP to induce USP29 transcription and stabilize p53 in response to oxidative stress.
Liu J; Chung HJ; Vogt M; Jin Y; Malide D; He L; Dundr M; Levens D
EMBO J; 2011 Mar; 30(5):846-58. PubMed ID: 21285945
[TBL] [Abstract][Full Text] [Related]
11. Alternative splicing of FBP-interacting repressor coordinates c-Myc, P27Kip1/cyclinE and Ku86/XRCC5 expression as a molecular sensor for bleomycin-induced DNA damage pathway.
Rahmutulla B; Matsushita K; Satoh M; Seimiya M; Tsuchida S; Kubo S; Shimada H; Ohtsuka M; Miyazaki M; Nomura F
Oncotarget; 2014 May; 5(9):2404-17. PubMed ID: 24811221
[TBL] [Abstract][Full Text] [Related]
12. CSIG promotes hepatocellular carcinoma proliferation by activating c-MYC expression.
Cheng Q; Yuan F; Lu F; Zhang B; Chen T; Chen X; Cheng Y; Li N; Ma L; Tong T
Oncotarget; 2015 Mar; 6(7):4733-44. PubMed ID: 25749381
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of RBM5 induces autophagy in human lung adenocarcinoma cells.
Su Z; Wang K; Li R; Yin J; Hao Y; Lv X; Li J; Zhao L; Du Y; Li P; Zhang J
World J Surg Oncol; 2016 Feb; 14():57. PubMed ID: 26923134
[TBL] [Abstract][Full Text] [Related]
14. Wogonin inhibits multiple myeloma-stimulated angiogenesis via c-Myc/VHL/HIF-1α signaling axis.
Fu R; Chen Y; Wang XP; An T; Tao L; Zhou YX; Huang YJ; Chen BA; Li ZY; You QD; Guo QL; Wu ZQ
Oncotarget; 2016 Feb; 7(5):5715-27. PubMed ID: 26735336
[TBL] [Abstract][Full Text] [Related]
15. Chemical suppression of an oncogenic splicing variant of AIMP2 induces tumour regression.
Lee HS; Kim DG; Oh YS; Kwon NH; Lee JY; Kim D; Park SH; Song JH; Lee S; Han JM; Park BJ; Lee J; Kim S
Biochem J; 2013 Sep; 454(3):411-6. PubMed ID: 23815603
[TBL] [Abstract][Full Text] [Related]
16. Fucoidan inhibition of lung cancer in vivo and in vitro : role of the Smurf2-dependent ubiquitin proteasome pathway in TGFβ receptor degradation.
Hsu HY; Lin TY; Wu YC; Tsao SM; Hwang PA; Shih YW; Hsu J
Oncotarget; 2014 Sep; 5(17):7870-85. PubMed ID: 25149540
[TBL] [Abstract][Full Text] [Related]
17. FBXO32 suppresses breast cancer tumorigenesis through targeting KLF4 to proteasomal degradation.
Zhou H; Liu Y; Zhu R; Ding F; Wan Y; Li Y; Liu Z
Oncogene; 2017 Jun; 36(23):3312-3321. PubMed ID: 28068319
[TBL] [Abstract][Full Text] [Related]
18. The ubiquitin E3 ligase ITCH enhances breast tumor progression by inhibiting the Hippo tumor suppressor pathway.
Salah Z; Itzhaki E; Aqeilan RI
Oncotarget; 2014 Nov; 5(21):10886-900. PubMed ID: 25350971
[TBL] [Abstract][Full Text] [Related]
19. Novel regulation of parkin function through c-Abl-mediated tyrosine phosphorylation: implications for Parkinson's disease.
Imam SZ; Zhou Q; Yamamoto A; Valente AJ; Ali SF; Bains M; Roberts JL; Kahle PJ; Clark RA; Li S
J Neurosci; 2011 Jan; 31(1):157-63. PubMed ID: 21209200
[TBL] [Abstract][Full Text] [Related]
20. SIAH-mediated ubiquitination and degradation of acetyl-transferases regulate the p53 response and protein acetylation.
Grishina I; Debus K; García-Limones C; Schneider C; Shresta A; García C; Calzado MA; Schmitz ML
Biochim Biophys Acta; 2012 Dec; 1823(12):2287-96. PubMed ID: 23044042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
